New Strategies For Therapeutic Antibodies – Synthetic bispecific antibodies & Antibody-Drug Conjugates with controlled drug loading. General methods for unexplored ADCs and personalised therapies.

Project Information

NSFTA

Grant agreement ID: 838703

DOI

10.3030/838703

Project closed

EC signature date 11 April 2019

Start date 15 January 2020

End date 9 March 2022

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 224 933,76

EU contribution

€ 224 933,76

Coordinated by

UNIVERSITY COLLEGE LONDON
United Kingdom

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (2)

A novel thiol-labile cysteine protecting group for peptide synthesis based on a pyridazinedione (PD) scaffold

Author(s): R.J. Spears; Clíona McMahon; Monika Shamsabadi; Calise Bahou; Ioanna A. Thanasi; Léa N. C. Rochet; Nafsika Forte; Fabien Thoreau; James R. Baker; Vijay Chudasama
Published in: CHEMICAL COMMUNICATIONS, Issue 1, 2022, Page(s) 645-648, ISSN 1359-7345
Publisher: Royal Society of Chemistry
DOI: 10.1039/d1cc03802h

Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry

Author(s): Fabien Thoreau; Vijay Chudasama
Published in: RSC Chemical Biology, Issue 1, 2022, Page(s) 140-169, ISSN 2633-0679
Publisher: Royal Society of Chemistry
DOI: 10.1039/d1cb00082a